Wall Street analysts expect that Integra Lifesciences Holdings Corp (NASDAQ:IART) will post $370.61 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Integra Lifesciences’ earnings. The highest sales estimate is $373.10 million and the lowest is $368.80 million. Integra Lifesciences reported sales of $278.83 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 32.9%. The company is expected to issue its next earnings results before the market opens on Thursday, October 25th.

On average, analysts expect that Integra Lifesciences will report full year sales of $1.49 billion for the current financial year, with estimates ranging from $1.48 billion to $1.49 billion. For the next year, analysts anticipate that the business will report sales of $1.57 billion, with estimates ranging from $1.56 billion to $1.60 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.60. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The company had revenue of $366.20 million during the quarter, compared to the consensus estimate of $368.08 million. During the same quarter in the prior year, the company posted $0.45 EPS. The company’s quarterly revenue was up 29.8% compared to the same quarter last year.

A number of brokerages have recently issued reports on IART. Morgan Stanley set a $68.00 target price on Integra Lifesciences and gave the stock a “hold” rating in a report on Thursday. Citigroup cut Integra Lifesciences from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $64.00 to $66.00 in a report on Monday, July 2nd. Zacks Investment Research cut Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. BTIG Research reiterated a “buy” rating and set a $69.00 target price on shares of Integra Lifesciences in a report on Thursday. Finally, BidaskClub cut Integra Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $62.15.

Shares of NASDAQ:IART traded up $1.30 during trading on Friday, reaching $61.96. 765,533 shares of the stock were exchanged, compared to its average volume of 723,541. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.27 and a current ratio of 3.52. Integra Lifesciences has a 12-month low of $41.51 and a 12-month high of $67.50. The stock has a market capitalization of $5.61 billion, a P/E ratio of 31.94, a PEG ratio of 2.03 and a beta of 0.57.

In other Integra Lifesciences news, VP Glenn Coleman sold 8,916 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $63.00, for a total value of $561,708.00. Following the completion of the transaction, the vice president now owns 16,795 shares in the company, valued at approximately $1,058,085. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jeffrey Mosebrook sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the transaction, the insider now owns 3,085 shares of the company’s stock, valued at approximately $192,565.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 111,140 shares of company stock valued at $7,054,647. 5.10% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IART. FMR LLC boosted its holdings in Integra Lifesciences by 11.8% in the 2nd quarter. FMR LLC now owns 11,078,120 shares of the life sciences company’s stock worth $713,542,000 after acquiring an additional 1,166,483 shares during the period. Millennium Management LLC purchased a new position in shares of Integra Lifesciences during the 2nd quarter valued at approximately $46,263,000. Westwood Holdings Group Inc. purchased a new position in shares of Integra Lifesciences during the 1st quarter valued at approximately $32,180,000. Janus Henderson Group PLC boosted its stake in shares of Integra Lifesciences by 22.8% during the 2nd quarter. Janus Henderson Group PLC now owns 1,966,341 shares of the life sciences company’s stock valued at $126,652,000 after buying an additional 365,254 shares during the last quarter. Finally, Castleark Management LLC purchased a new position in shares of Integra Lifesciences during the 2nd quarter valued at approximately $18,130,000. Hedge funds and other institutional investors own 84.41% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.